Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY2A | P04746 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.38 |
| ▸ | PYGB | P11216 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.36 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19656175 | 1.00 | AMY2A (0.40) | AMY2AOGAPYGBSLC5A2LGALS8 | |
| SCHEMBL15308088 | 1.00 | AMY2A (0.40) | AMY2AOGAPYGBSLC5A2LGALS8 | |
| SCHEMBL25574842 | 0.94 | OGA (0.41) | AMY2AOGAPYGBSLC5A2LGALS8 | |
| SCHEMBL19778307 | 0.92 | PYGB (0.41) | AMY2AOGAPYGBSLC5A2LGALS8 | |
| SCHEMBL21141258 | 0.90 | PYGB (0.44) | AMY2AOGAPYGBSLC5A2LGALS8 | |
| SCHEMBL280552 | 0.86 | OGA (0.44) | AMY2AOGAPYGBLGALS8LGALS1 | |
| SCHEMBL14366120 | 0.85 | CA2 (0.33) | AMY2AOGAPYGBSLC5A2 | |
| SCHEMBL12872378 | 0.84 | OGA (0.38) | AMY2AOGAPYGBSLC5A2LGALS8 | |
| SCHEMBL22425801 | 0.83 | FBP1 (0.40) | AMY2AOGAPYGBSLC5A2LGALS8 | |
| SCHEMBL7745123 | 0.82 | AMY2A (0.43) | AMY2AOGAPYGBSLC5A2LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636355-B2 | Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion | THEO HOLDINGS, LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-20130079301-A1 | Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion | THEO HOLDINGS, LLC | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079301-A1 | Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion | DSC1, CD44, CRYAB | AMY2A 4523/4885OGA 272/4885PYGB 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.